Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors

Xilio Therapeutics, Inc.

Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.
Phase 1C: 2 unconfirmed PRs (MSS CRC with liver lesion resolution, ampullary carcinoma); no Grade 4/5 treatment-related AEs.
RP2D selected: vilastobart 100 mg Q6W + atezolizumab 1200 mg Q3W; Phase 2 enrolling MSS CRC.
Initial Phase 2 data for vilastobart combo in ~20 MSS CRC patients expected Q4 2024; ~40 total by Q1 2025.
License revenue $2.3M from Gilead agreement; net loss $14.0M vs $16.7M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.